Acetazolamide is a well-established carbonic anhydrase inhibitor widely used as an active pharmaceutical ingredient (API) in various therapeutic areas. At TCS GROUP, our acetazolamide offering meets high-purity standards, making it ideal for formulation into tablets, capsules, or parenteral systems. According to pharmacological data, acetazolamide functions by inhibiting the enzyme carbonic anhydrase, thereby reducing aqueous humor formation in the eye (glaucoma), altering renal bicarbonate reabsorption (diuresis), and modulating neuronal discharge in certain seizure disorders.
From a manufacturing perspective, formulators appreciate acetazolamide’s predictable behaviour, regulatory history (CAS 59-66-5), and compatibility with standard excipient systems. When sourcing from TCS INDUSTRIES LIMITED, you gain the benefit of rigorous quality control, COA traceability, and full documentation support. For example, formulators working on immediate-release tablets may pair acetazolamide with a high-performance superdisintegrant such as our Croscarmellose Sodium Superdisintegrant to ensure prompt tablet breakup and enhanced bioavailability.
For a streamlined supply chain, consider bundling acetazolamide with other APIs or excipients from TCS GROUP—for instance, our peptide-based actives like Acetyl Decapeptide-3 (for cosmetic pipelines) or our more specialized APIs like Ademetionine Disulfate Tosylate for liver-support therapies. Whether you’re innovating in neurology, ophthalmology or generic tablets, our API range helps you scale with confidence.